Alkermes (ALKS) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alkermes (ALKS) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 57.1% versus a loss of 38.5%. Over five years, ALKS leads with a +100.0% price change compared with +92.8% for SMMT. Summit Therapeutics is the larger company by market cap ($7.96 billion vs $7.55 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | SMMT |
|---|---|---|
| Share price | $44.94 | $9.95 |
| Market cap | $7.55B | $7.96B |
| 1-day change | -2.69% | -5.87% |
| YTD return | +60.61% | -43.11% |
| 1-year return | +57.08% | -38.54% |
| 5-year return | +100.00% | +92.83% |
| Forward P/E | 33.21 | — |
| EPS (TTM) | $-0.01 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | — |
| Revenue growth (YoY) | -5.25% | — |
| Net income (latest FY) | $241.66M | $-1.08B |
| Gross margin | 86.69% | — |
| Operating margin | 17.21% | — |
| Net margin | 16.37% | — |
| 52-week high | $55.67 | $29.23 |
| 52-week low | $27.00 | $9.89 |
| Distance from 52-week high | -19.27% | -65.96% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +28.48% | +189.15% |
| Average volume | 1.90M | 6.68M |
| Shares outstanding | 168.04M | 799.76M |
| Employees | 2,050 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALKS has outperformed SMMT by 95.6 percentage points over the past year.
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
ALKS vs SMMT FAQ
Which is bigger, Alkermes or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $7.96B compared with $7.55B for Alkermes (ALKS).
Which stock has performed better over the past year, ALKS or SMMT?
ALKS returned +57.08% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.